An Update on the Treatment of Helicobacter Pylori Infection - European Medical Journal

An Update on the Treatment of Helicobacter Pylori Infection

Download PDF
*Sinéad Marian Smith

The author has declared no conflicts of interest.

EMJ Gastroenterol. ;4[1]:101-107. DOI/10.33590/emjgastroenterol/10310813.
Helicobacter pylori, triple therapy, bismuth quadruple therapy, sequential therapy, concomitant therapy, hybrid therapy, antibiotic resistance.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.


Helicobacter pylori treatment is becoming a challenge in light of increasing antimicrobial resistance and falling eradication rates. This is a cause for concern based on the complications of H. pylori infection, which include gastric and peptic ulcers, gastric cancer, and mucosa-associated lymphoid tissue lymphoma. This review discusses recent data assessing the current treatment options for H. pylori infection and the importance of considering the prevalence of antibiotic resistance at a regional level when choosing an appropriate therapy. Alternatives to the standard first-line treatment, such as bismuth and non-bismuth quadruple therapies, are outlined and rescue therapies involving levofloxacin and rifabutin are also reviewed.

Please view the full content in the pdf above.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now